Koyfin Home > Directory > Health Care > Aimmune Therap > Capital Expenditures

Aimmune Therap Capital Expenditures Chart (AIMT)

Aimmune Therap annual/quarterly Capital Expenditures from 2014 to 2020.
  • Aimmune Therap Capital Expenditures for the quarter ending June 06, 2020 was $0m a -357.79% increase of 2m year over year
  • Aimmune Therap Capital Expenditures for the last 12 months ending June 06, 2020 was $-4m a -105.66% increase of 4m year over year
  • Aimmune Therap Annual Capital Expenditures for 2019 was $-8m a -17.06% increase of 1m from 2018
  • Aimmune Therap Annual Capital Expenditures for 2018 was $-9m a 31.79% decrease of -3m from 2017
  • Aimmune Therap Annual Capital Expenditures for 2017 was $-6m a -19.30% increase of 1m from 2016
Other Cash Flow Metrics:
  • Aimmune Therap Cash Flow from Operations for the quarter ending September 09, 2018 was $-41m a 22.62% decrease of -9m year over year
  • Aimmune Therap Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-25m a 30.11% decrease of -7m year over year
View Chart On Koyfin

Quarterly AIMT Capital Expenditures Data

06/2020$0m
03/2020$0m
12/2019$-1m
09/2019$-2m
06/2019$-3m
03/2019$-1m
12/2018$-1m
09/2018$-2m
06/2018$-4m
03/2018$-2m

Annual AIMT Capital Expenditures Data

2019$-8m
2018$-9m
2017$-6m
2016$-8m
2015$-2m
2014$0m
2013$0m